BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8076380)

  • 1. p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study.
    Sorsdahl K; Casson AG; Troster M; Van Meyel D; Inculet R; Chambers AF
    Cancer Detect Prev; 1994; 18(3):179-85. PubMed ID: 8076380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
    von Rahden BH; Stein HJ; Feith M; Pühringer F; Theisen J; Siewert JR; Sarbia M
    Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
    Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
    Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
    Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene mutations in Barrett's epithelium and esophageal cancer.
    Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA
    Cancer Res; 1991 Aug; 51(16):4495-9. PubMed ID: 1868473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
    Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53.
    Iannettoni MD; Lee SS; Bonnell MR; Sell TL; Whyte RI; Orringer MB; Beer DG
    Ann Thorac Surg; 1996 Nov; 62(5):1460-5; discussion 1465-6. PubMed ID: 8893584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
    Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
    Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53-mutant clones and field effects in Barrett's esophagus.
    Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
    Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.